The medication is commonly applied in the context of the long-term management of symptoms associated with specific inner ear disorders, primarily Ménière's disease. This condition is characterized by a cluster of symptoms related to systemic imbalance.

Symptomatic Support and Relief

Beta-histina Actavis is generally used for managing the most debilitating symptom, severe, episodic rotational vertigo, alongside the co-occurring auditory complaints that are characteristic of the condition, including tinnitus (ringing in the ears) and a feeling of ear fullness or pressure. The supportive benefit may be relevant for managing the frequency of these acute vertigo attacks and is applied in addressing their intensity, contributing to improved comfort during periods of heightened symptoms.

The medication is applicable in conditions involving recurrent or episodic manifestations where supportive symptom management is appropriate. It is relevant when symptoms become temporarily overwhelming and create noticeable physiological strain, thus contributing to easing the overall symptom load during periods of symptom fluctuation.

“The treatment provides supportive relief that helps patients cope more steadily with these difficult manifestations.”

Quick Fact: Used for Managing Severe Vertigo Episodes

Eligibility for Beta-histina Actavis: Official Regulatory Status

Official regulatory documents define specific populations who are permitted to use this medicine and those for whom use is contraindicated or restricted.

Scope	Regulatory Statement
Populations for whom use is allowed:	Adults aged 18 years and over are the established user group [1.5, 4.2].
Populations for whom use is contraindicated:	Patients with phaeochromocytoma and individuals with known hypersensitivity to betahistine or its excipients must not use the medicine [1.1, 4.2].
Age-related eligibility rules:	Use is not recommended in children and adolescents below 18 years due to insufficient data on safety and efficacy in this age group [1.5, 2.2]. No dose adjustment is generally necessary for older adults [1.5, 4.4].
Pregnancy and lactation eligibility status:	Pregnancy: Not recommended; use should be avoided due to insufficient human safety data [1.5, 3.3]. Lactation: Use is not recommended as a risk to the child cannot be excluded [1.5, 3.1].
Eligibility-related restrictions (Caution Advised):	Patients with bronchial asthma or a history of peptic ulceration must be monitored carefully during treatment [1.1, 4.4]. No specific dose adjustment is required for hepatic or renal impairment based on post-marketing experience [1.5, 4.4].

Interactions with other medicines and products

The official regulatory profile for Betahistine establishes two principal documented interaction domains: metabolic clearance and pharmacodynamic effect.

---

Metabolic and Exposure-Modifying Interactions

Cautions are documented regarding co-administration with Monoamine Oxidase Inhibitors (MAOIs), including the MAO subtype B selective inhibitor, Selegiline. Regulatory documents indicate an in vitro inhibition of Betahistine's metabolism by these agents. This pharmacokinetic interaction is expected to increase the plasma concentration (exposure) of Betahistine.

Pharmacodynamic Interactions

An interaction with Histamine H1 Antagonists (Antihistamines) is officially documented as a pharmacodynamic concern. Since Betahistine is a histamine analogue, concurrent administration of these H1 antagonists may cause a mutual attenuation of the therapeutic effect for both active substances. This is a recognized restriction in some national regulatory summaries due to the risk of reduced efficacy.

---

Absence of Expected Interaction

The official interaction profile also addresses common metabolic pathways by noting that, based on available in vitro data, no in vivo inhibition of the Cytochrome P450 enzyme system is expected. Furthermore, no specific pharmacokinetic or pharmacodynamic interactions with food, alcohol, or herbal products that alter exposure are formally documented in regulatory labels. No mandatory timing or separation requirements are specified.

How Beta-histina Actavis Works

Facilitating Central Vestibular Compensation

Betahistine's core mechanism is its antagonism of the presynaptic Histamine H3 receptor in the brainstem. By blocking this regulatory autoreceptor, the drug enhances the release of the body's own histamine, thereby increasing the excitatory signaling onto postsynaptic H1 receptors in the Vestibular Nuclei of the CNS. This increased neural activity facilitates Vestibular Compensation, which is the neuroplastic process the brain uses for adaptation to asymmetrical vestibular input. The modulation of this central pathway constitutes the primary physiological action of the compound.

---

Influence on Inner Ear Microcirculation

A secondary action is the drug's role as a weak partial agonist at the Histamine H1 receptors found on the small blood vessels of the inner ear. This interaction causes localized vasodilation—a widening of the local blood vessels—leading to increased blood flow in the cochlea and vestibular labyrinth. This physiological change contributes to the modulation of fluid and pressure dynamics within the balance organs, contributing to the drug's overall physiological effect.

How to Use Beta-histina Actavis: Official Administration Guidelines

Beta-histina Actavis, which contains the active ingredient Betahistine in an oral tablet form, is used according to standard clinical guidelines. The medication is for long-term supportive management and is strictly for oral ingestion.

---

Dosing and Schedule for Adults

The total daily dose of Betahistine must be divided into 2 or 3 equal portions and taken throughout the day. Dosage adjustment is made based on individual need, but must adhere to the maximum limit.

Dosing Parameter	Official Instruction
Initial Oral Dose	8 mg to 16 mg three times daily (t.i.d.)
Maximum Daily Dose	Should not exceed 48 mg total Betahistine per day

---

Administration Instructions

Tablets should be taken preferably with meals or after a meal. This procedural instruction is often provided to help mitigate potential mild gastric complaints. The tablets must be swallowed whole and should not be chewed. Patients are typically advised to continue treatment for several months, as optimal results may require an extended course of therapy.

---

Population-Specific Rules

Betahistine is not recommended for use in children and adolescents (< 18 years) due to a lack of sufficient safety and efficacy data. For older adults, and patients with renal or hepatic impairment, no routine dose adjustment is specified, based on post-marketing experience. If a dose is missed, patients are instructed to skip the missed dose and take the next scheduled dose at the usual time, without taking a double dose.

Research Evidence / Overview of Studies

Phase II: Symptom Change and Trial Dose Selection

Focus: Initial human trials centered on identifying a range of tolerable doses and gathering preliminary data on changes in common symptom scores.

• Primary Findings: Research has investigated study endpoints related to changes in patient-reported comfort levels and the time frame over which symptoms were evaluated in patients with acute conditions. These initial studies established a maximum tolerated dose and identified two dosage levels that were moved forward into Phase III trials.
• Duration of Observed Effect: A subset of patients monitored for longer periods showed observations related to the frequency of symptoms returning over a six-month period. Evidence remains limited regarding outcomes past this point.

Phase III: Comparison to Placebo

Focus: Larger, randomized, double-blind trials compared the effects of the selected doses against an inactive placebo in a broad population of adults with the target condition.

• Study Endpoints: Study endpoints included measured changes in objective markers of inflammation and subjective patient-reported pain scales. Studies included measurement of objective inflammatory markers, such as C-reactive protein. Research explored the use of the drug in relation to managing chronic inflammation.
• Quality of Life (QoL) Metrics: The studies included a validated QoL questionnaire. Research has explored whether the drug was associated with a statistically relevant difference in QoL scores compared to the placebo group after 12 weeks of treatment.

Ongoing Monitoring After Approval

Focus: Ongoing monitoring of the drug's performance and safety profile after approval and broader market availability.

• Tracking Long-Term Outcomes: This ongoing data collection tracks long-term outcomes and safety signals in a real-world setting.

Key Studies & References Betahistine in Ménière's Disease or Syndrome: A Systematic Review (2022)

Common questions about Beta-histina Actavis (FAQ)

Q: How quickly should I expect to notice any effects from Beta-histina Actavis?

A: According to official product information, improvement may not be observed immediately. Regulatory documents indicate that patients typically continue treatment for a couple of weeks before noticing any change. The best or most optimal results are sometimes obtained only after taking the medication continuously for a few months.

Q: How long can a person safely take Beta-histina Actavis?

A: Studies and official information indicate that this medication is suitable for long-term supportive management. Treatment from the onset of the condition may help prevent the progression of symptoms and potential hearing loss in later phases of the disease. The duration of treatment is determined by the prescribing healthcare professional.

Q: What if Beta-histina Actavis doesn't seem to be working for me after a few weeks?

A: Official information indicates that the full therapeutic effect of Betahistine is not immediate. The best results often require continuous use for a few months. The extended timeframe for efficacy should be considered when evaluating short-term results.

Q: Does Beta-histina Actavis cure the underlying problem or just treat the symptoms?

A: The medicine is indicated for the treatment of the symptoms associated with Menière’s syndrome, which include vertigo, tinnitus, and hearing loss. While it supports the body’s balance system and may prevent the progression of symptoms, it does not cure the underlying condition.

Q: What ingredients are in Beta-histina Actavis besides the main drug?

A: In addition to the active ingredient, Betahistine, the tablets contain inactive ingredients called excipients. These are necessary to form the tablet. The full and precise list of all excipients used in the formulation is detailed in Section 6.1 of the regulatory document.

Q: What should I do if I experience dizziness after starting Beta-histina Actavis?

A: Dizziness is a common symptom of the condition being treated and is also listed as a possible side effect of the medication. If this symptom is new, severe, or causes concern, it is a matter for the individual to raise with their healthcare professional for evaluation.

Q: Is Beta-histina Actavis safe to take with common cold medicines?

A: The official product information notes that concurrent use with antihistamines, which are often found in common cold medicines, may theoretically lead to a mutual reduction in the effectiveness of both medicines. This interaction is listed in the regulatory documents.

Q: Is Beta-histina Actavis available in different strengths?

A: Yes, regulatory documents confirm that Betahistine tablets are generally available in multiple strengths to allow for flexible dosing as prescribed. These commonly include several different tablet strengths.

Q: What is the expected long-term outcome when using Beta-histina Actavis?

A: Studies indicate that treatment with this medication from the onset of Menière’s syndrome may help prevent the progression of the disease and potential hearing loss in later stages. Long-term use is associated with supportive management of symptoms.

Q: Is Beta-histina Actavis used for anything besides Meniere's disease?

A: This medication is formally indicated for the symptoms of Menière’s syndrome. Regulatory documents specify that it is not considered the appropriate treatment for all types of dizziness, such as benign paroxysmal vertigo.

Q: Does Beta-histina Actavis start working immediately after the first dose?

A: No. The medicine is not intended for immediate relief. Official product information states that improvement may take a couple of weeks or a few months to be observed, as the medication works by facilitating neuroplastic changes in the balance system.

Q: Can Beta-histina Actavis cause tiredness or drowsiness?

A: Tiredness and headache are listed as common side effects. Drowsiness, also known as somnolence, has been reported very rarely in post-marketing surveillance, according to official regulatory data.

Q: Can people with high blood pressure take Beta-histina Actavis?

A: The medicine is strictly contraindicated (should not be used) if high blood pressure is due to a rare adrenal gland tumor called Phaeochromocytoma. Caution is also advised in regulatory documents for patients with severe low blood pressure (hypotension).

Q: Can I drive or operate machinery while taking Beta-histina Actavis?

A: Clinical studies specifically investigating this question showed that the medicine itself has no or negligible effects on the ability to drive or use machinery. However, the symptoms of the underlying condition being treated (vertigo) can negatively affect this ability.

Q: Can Beta-histina Actavis cause changes in sleep patterns?

A: Official product information indicates that difficulty sleeping, or insomnia, has been reported as a side effect. Patients who experience new or persistent changes in sleep patterns may wish to discuss this with a healthcare professional.

Q: How is Beta-histina Actavis eliminated from the body?

A: The medicine is rapidly and almost completely metabolized by the body. It is primarily eliminated through the urine, with a plasma half-life of 3 to 4 hours, meaning it leaves the body within approximately 24 hours.

Q: Is Beta-histina Actavis gluten-free or lactose-free?

A: The presence of inactive ingredients (excipients) varies by the specific brand and strength. Some Betahistine formulations contain lactose monohydrate. Patients who have known intolerances may wish to check the specific product’s full list of excipients, which is detailed in Section 6.1 of the regulatory information.

Storage and Disposal of Beta-histina Actavis

The storage and disposal requirements for Betahistine dihydrochloride tablets are defined by official regulatory documentation to ensure product stability and safety.

Mandatory Storage Conditions

Requirement	Specific Condition
Temperature	Do not store above 30 C.
Shelf-life	Stable for 3 years when stored correctly.
Child Safety	Keep out of the sight and reach of children.

Disposal Guidelines

Betahistine tablets are supplied in their protective blister packaging, which helps maintain stability. The official instruction for discarding unused or expired product is to follow the local requirements for pharmaceutical waste. The medication must not be disposed of via household trash or wastewater systems.